RedHill Biopharma Ltd - Company Profile
Powered by 
All the sales intelligence you need on RedHill Biopharma Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how RedHill Biopharma Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with RedHill Biopharma Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
RedHill Biopharma Ltd (RedHill) is a specialty biopharmaceutical company. It is involved in the research, development and manufacturing of therapeutics for the treatment of gastrointestinal and infectious diseases. The company’s product portfolio includes Talicia, an oral capsule for Helicobacter pylori. RedHill’s product pipeline includes opaganib for gastrointestinal acute radiation syndrome (GI-ARS), COVID-19, various viral infections, inflammatory conditions, solid tumors, cholangiocarcinoma and metastatic castration-resistant prostate cancer. It is also developing RHB-107 for early COVID-19 outpatient treatment; RHB-102 for chemotherapy-induced nausea and IBS-D; RHB-204 for Crohn’s disease and multiple sclerosis. RedHill is headquartered in Tel Aviv, Israel.
Headquarters
Israel
Address
21 Ha’arba’a Street, Tel Aviv, 6473921
Website
www.redhillbio.com
Telephone
972 3 5413131
No of Employees
13
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RDHL (NASD)
Revenue (2024)
$286,000
EPS
XYZ
Net Income (2024)
XYZ
94.8%
(2024 vs 2023)
Market Cap*
$4.0M
Net Profit Margin (2024)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
RedHill Biopharma Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed Prescription Drugs: | Talicia |
| Talicia: H. pylori bacterial infection | |
| Product Pipeline: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In February, the company announced he full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. |
| 2025 | Contracts/Agreements | In October, the company signed a partnership to sell a 30% stake in its Talicia business to Cumberland Pharmaceuticals Inc. for US$4 million. |
| 2025 | Contracts/Agreements | In October, the company signs new US$1.8 million plus sales royalties Middle East deal for Talicia. |
Competitor Comparison
| Key Parameters | RedHill Biopharma Ltd | AbbVie Inc | Phathom Pharmaceuticals Inc | Hayat Pharmaceutical Industries | BioLineRx Ltd |
|---|---|---|---|---|---|
| Headquarters | Israel | United States of America | United States of America | Jordan | Israel |
| City | Tel Aviv | North Chicago | Florham Park | Amman | Modi'in-Maccabim-Re'ut |
| State/Province | Tel Aviv | Illinois | New Jersey | - | - |
| No. of Employees | 13 | 57,000 | 371 | 191 | 24 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dr Richard Peters | Chairman | Executive Board | 2023 | 63 |
| Fabrice Chouraqui | Chief Executive Officer; Chairman | Executive Board | 2025 | 55 |
| Dr Mark Pykett | Director; Vice Chairman | Executive Board | - | 61 |
| Kenneth Lynard | Chief Financial Officer | Senior Management | - | 57 |
| Ruud van Outersterp | Secretary; Chief Legal Officer | Senior Management | 2025 | 61 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer